EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022
   Pooled it
2. Impact of nonalcoholic fatty liver disease on atrial fibrillation recurrence after catheter ablation: a prospective cohort study.Frontiers in cardiovascular medicine · 2026
   Article
3. Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.World journal of cardiology · 2025
   Review
4. Association between type 1 diabetes mellitus and esophageal varices: a Mendelian randomization study.Archives of medical science : AMS · 2025
   Article
5. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012).Nutrients · 2022
   Article
6. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults.Aging · 2021
   Article
7. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart.International journal of molecular sciences · 2021
   Review
8. Associations between serum lipophilic antioxidants levels and non-alcoholic fatty liver disease are moderated by adiposity.European journal of clinical nutrition · 2019
   Article
9. PKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity.Bioscience reports · 2017
   Article
10. High mobility group box 1 in diabetic nephropathy.Experimental and therapeutic medicine · 2017
    Article
11. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.Visceral medicine · 2016
    Review
12. Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury.Frontiers in pharmacology · 2016
    Review

Corrections and comments

• Comment on
  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as